Global Preventive Vaccines Market Market Companies
Moderna, Inc., Pfizer Inc., Merck & Co., Inc., and others are the major companies in the preventive vaccines market. These major competitors are using tactics to propel the expansion of the preventive vaccines market, including boosting R&D expenditures, forming strategic alliances and partnerships, implementing digital and AI-driven marketing strategies, and fortifying supply chain and cold chain logistics.
List of Key Players in the Market:
- Moderna, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Minervax
- GSK plc.
- Sanofi
- AstraZeneca
- Bharat Biotech
- Valneva SE
- VBI Vaccines Inc.
- GSBPL
- Serum Institute of India Pvt. Ltd.
- CSL
- SINOVAC
- Johnson & Johnson Services, Inc.
Recent News:
- Vaccine Alliance supporter Gavi said lower-income nations might seek to implement four more vaccines: the hepatitis B birth dose, the multivalent meningococcal conjugate, the human rabies vaccine for post-exposure prophylaxis, and the preventive Ebola vaccine, in June 2024. These four vaccination programs were originally authorized by the Gavi Board but were halted due to the COVID-19 pandemic, the need for adequate policy recommendations (preventive Ebola), or the lack of suitable goods (multivalent meningococcal conjugate).
- According to Merck, the U.S. Food and Drug Administration (FDA) has authorized CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for active vaccination against invasive disease caused by Streptococcus pneumoniae serotypes and active vaccination against pneumonia caused by S. pneumoniae serotypes in people aged 18 and up, in June 2024.
- R21/Matrix-M, a novel vaccine, was suggested by the World Health Organization (WHO) to prevent childhood malaria, in October 2023. Following its usual biannual meeting, the WHO Director-General approved the suggestion, which was in accordance with the recommendations of the Malaria Policy Advisory Group (MPAG) and the WHO Strategic Advisory Group of Experts on Immunization (SAGE).
- ABRYSVO (Respiratory Syncytial Virus Vaccine), Pfizer Inc.'s bivalent RSV prefusion F (RSVpreF) vaccine, was approved by the U.S. Food and Drug Administration (FDA) to prevent LRTD and severe LRTD caused by RSV in infants from birth to six months of age by actively immunizing pregnant women between 32 and 36 weeks gestation, in August 2023. Comprising two preF proteins chosen to maximize defense against RSV A and B strains, ABRYSVO was unadjuvanted and shown to be both safe and effective.
- According to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting, PreHevbrio [Hepatitis B Vaccine (Recombinant)] has been added to the list of recommended products for prophylactic adult vaccination against hepatitis B (HBV) infection, in February 2022. This announcement was made by VBI Vaccines Inc., a biopharmaceutical company that is motivated by immunology in its pursuit of potent disease prevention and treatment.